Marcio Fronza1,2, Cornélia Muhr3, Denise Sayuri Calheiros da Silveira1, Carlos Artério Sorgi1, Stephen Fernandes de Paula Rodrigues4, Sandra Helena Poliselli Farsky4, Francisco Wanderley Garcia Paula-Silva1, Irmgard Merfort3, Lúcia Helena Faccioli5. 1. Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14040-903, Brazil. 2. Departamento de Farmácia, Universidade Vila Velha, Vila Velha, Espirito Santo, Brazil. 3. Department of Pharmaceutical Biology and Biotechnology, University of Freiburg, Freiburg, Germany. 4. Department of Clinical and Toxicological Analyses, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil. 5. Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, 14040-903, Brazil. faccioli@fcfrp.usp.br.
Abstract
OBJECTIVE: To evaluate the in vivo anti-inflammatory potential of bovine hyaluronidase (HYAL) using two different models of acute inflammation. METHODS: Air pouches were produced in the dorsal subcutaneous of mice and injected with phosphate saline solution or HYAL. The antiinflammatory action of HYAL was evaluated in carrageenan (Cg)-inflamed air pouches. After 4 and 24 h the cellular influx, protein exudation, cytokines and lipid mediators were evaluated. The action of HYAL on the rolling and adhesion of leukocytes was investigated in the LPS-stimulated mesenteric microcirculation by intravital microscopic. RESULTS: Treatment with HYAL reduced the cellular influx and protein exudation in non-inflamed and inflamed air pouches. HYAL treatment of Cg-inflamed air pouch reduced the production of tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), leukotriene B4 (LTB4) and LTC4, whereas prostaglandins E2 (PGE2) and D2 (PGD2) concentrations were unchanged. Histological analyses showed that HYAL administration diminished cell infiltration in the air-pouch lining. In LPS-stimulated mesenteric microcirculation, HYAL usage decreased rolling and adhesion of leukocytes, but did not affect the blood vessels diameters. CONCLUSION: The results demonstrate that HYAL inhibited cellular recruitment, edema formation and pro-inflammatory mediators production, resulting in decreased adherence of leukocytes to blood vessels and tissue infiltration. Our data suggest that HYAL may be considered an effective candidate to ameliorate acute inflammation.
OBJECTIVE: To evaluate the in vivo anti-inflammatory potential of bovine hyaluronidase (HYAL) using two different models of acute inflammation. METHODS: Air pouches were produced in the dorsal subcutaneous of mice and injected with phosphate saline solution or HYAL. The antiinflammatory action of HYAL was evaluated in carrageenan (Cg)-inflamed air pouches. After 4 and 24 h the cellular influx, protein exudation, cytokines and lipid mediators were evaluated. The action of HYAL on the rolling and adhesion of leukocytes was investigated in the LPS-stimulated mesenteric microcirculation by intravital microscopic. RESULTS: Treatment with HYAL reduced the cellular influx and protein exudation in non-inflamed and inflamed air pouches. HYAL treatment of Cg-inflamed air pouch reduced the production of tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), leukotriene B4 (LTB4) and LTC4, whereas prostaglandins E2 (PGE2) and D2 (PGD2) concentrations were unchanged. Histological analyses showed that HYAL administration diminished cell infiltration in the air-pouch lining. In LPS-stimulated mesenteric microcirculation, HYAL usage decreased rolling and adhesion of leukocytes, but did not affect the blood vessels diameters. CONCLUSION: The results demonstrate that HYAL inhibited cellular recruitment, edema formation and pro-inflammatory mediators production, resulting in decreased adherence of leukocytes to blood vessels and tissue infiltration. Our data suggest that HYAL may be considered an effective candidate to ameliorate acute inflammation.
Authors: V E Steele; C A Holmes; E T Hawk; L Kopelovich; R A Lubet; J A Crowell; C C Sigman; G J Kelloff Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-05 Impact factor: 4.254
Authors: Bryan G Yipp; Graciela Andonegui; Christopher J Howlett; Stephen M Robbins; Thomas Hartung; May Ho; Paul Kubes Journal: J Immunol Date: 2002-05-01 Impact factor: 5.422
Authors: Eric Diego Barioni; José Roberto Santin; Isabel Daufenback Machado; Stephen Fernandes de Paula Rodrigues; Viviane Ferraz-de-Paula; Theodoro Marcel Wagner; Bruno Cogliati; Matheus Corrêa Dos Santos; Marina da Silva Machado; Sérgio Faloni de Andrade; Rivaldo Niero; Sandra Helena Poliselli Farsky Journal: Evid Based Complement Alternat Med Date: 2013-02-11 Impact factor: 2.629
Authors: Bruno A C Nascimento; Luiz G Gardinassi; Inaê M G Silveira; Marília G Gallucci; Mariana A Tomé; Júlia Fernanda D Oliveira; Mirella R A Moreira; Alyne F G Meirelles; Lúcia H Faccioli; Cristiane Tefé-Silva; Karina F Zoccal Journal: Medicines (Basel) Date: 2019-07-29
Authors: Svetlana I Galkina; Natalia V Fedorova; Alexander L Ksenofontov; Ekaterina A Golenkina; Marina V Serebryakova; Vladimir I Stadnichuk; Ludmila A Baratova; Galina F Sud'ina Journal: Biomedicines Date: 2022-01-28